Deal-Ticker: Vifor Pharma acquires Inositec
Vifor Pharma acquires the Swiss firm Inositec AG, a clinical stage biopharmaceutical company which is developing first-in-class treatments for unmet medical need. Through these acquisitions, Vifor Pharma will be spearheading the vascular calcification field to improve lives of more than 600'000 patients in U.S. and EU suffering from peripheral artery disease. Subject to the closing, the shareholders of Inositec AG will receive a fixed consideration of CHF 20 million and possible milestone payments in the low three-digit million range.
Kellerhals Carrard (Beat Brechbühl, Nicolai Nuber and Shayan Mirabi) provided comprehensive legal advice to Vifor Pharma on the transaction.